armodafinil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4501 112111-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nuvigil
  • CEP-10953
  • armodafinil
  • R-modafinil
  • Molecular weight: 273.35
  • Formula: C15H15NO2S
  • CLOGP: 0.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 60.16
  • ALOGS: -2.64
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.06 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 53
kinase-selectivity-class AXL,ERBB2,GRK2,MAP2K6,PDK4,SIK2,TEK 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1

Approvals:

DateAgencyCompanyOrphan
June 5, 2007 FDA CEPHALON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product administration interrupted 445.77 15.01 143 17108 12349 90598847
Pre-existing condition improved 298.76 15.01 98 17153 9071 90602125
Anxiety 242.18 15.01 296 16955 309476 90301720
Sleep apnoea syndrome 233.14 15.01 116 17135 31631 90579565
Suicidal ideation 210.26 15.01 146 17105 73709 90537487
Depression 184.43 15.01 255 16996 300346 90310850
Somnambulism 153.48 15.01 54 17197 6174 90605022
Therapeutic response unexpected 129 15.01 69 17182 21811 90589385
Surgery 128.29 15.01 89 17162 44798 90566398
Feeling abnormal 116.32 15.01 151 17100 167084 90444112
Somnolence 101.44 15.01 159 17092 208925 90402271
Multiple sclerosis relapse 92.66 15.01 78 17173 52227 90558969
Cataplexy 82.34 15.01 24 17227 1496 90609700
Enuresis 81.82 15.01 29 17222 3385 90607811
Snoring 77.22 15.01 31 17220 5095 90606101
Blood pressure increased 75.60 15.01 135 17116 197082 90414114
Feeling jittery 75.54 15.01 43 17208 15328 90595868
Tremor 70.81 15.01 114 17137 153059 90458137
Infusion related reaction 66.68 15.01 3 17248 416777 90194419
Panic attack 58.77 15.01 45 17206 26320 90584876
Headache 58.41 15.01 320 16931 862426 89748770
Stress 54.20 15.01 72 17179 81323 90529873
Fall 53.61 15.01 207 17044 481603 90129593
General physical health deterioration 52.40 15.01 4 17247 355111 90256085
Intentional dose omission 50.17 15.01 35 17216 17748 90593448
Sleep paralysis 47.85 15.01 14 17237 884 90610312
Hangover 46.47 15.01 17 17234 2172 90609024
Weight decreased 45.35 15.01 167 17084 379743 90231453
Treatment failure 43.25 15.01 4 17247 303924 90307272
Bruxism 41.31 15.01 19 17232 4344 90606852
Restless legs syndrome 40.79 15.01 34 17217 22436 90588760
Narcolepsy 40.50 15.01 14 17237 1518 90609678
Unevaluable event 40.38 15.01 51 17200 54797 90556399
Illness 39.21 15.01 62 17189 81907 90529289
Bipolar disorder 38.50 15.01 23 17228 8962 90602234
Insomnia 38.45 15.01 145 17106 333329 90277867
Initial insomnia 37.74 15.01 23 17228 9287 90601909
Memory impairment 37.61 15.01 102 17149 197142 90414054
Glossodynia 37.05 15.01 8 17243 321771 90289425
Multiple sclerosis 36.40 15.01 35 17216 27805 90583391
Impaired driving ability 35.30 15.01 18 17233 5155 90606041
Joint swelling 34.75 15.01 27 17224 503273 90107923
Sleep-related eating disorder 33.78 15.01 11 17240 993 90610203
Seizure 33.27 15.01 83 17168 152546 90458650
Paranoia 33.17 15.01 24 17227 12884 90598312
Head injury 33.06 15.01 35 17216 31153 90580043
Lower respiratory tract infection 31.49 15.01 5 17246 250654 90360542
Discomfort 31.21 15.01 7 17244 274328 90336868
Systemic lupus erythematosus 31.11 15.01 15 17236 361881 90249315
Drug intolerance 30.90 15.01 24 17227 447567 90163629
Feeling drunk 30.86 15.01 16 17235 4742 90606454
Vitamin D deficiency 30.70 15.01 26 17225 17530 90593666
Product use in unapproved indication 30.36 15.01 13 17238 336223 90274973
Hysterectomy 28.55 15.01 21 17230 11563 90599633
Wound 28.51 15.01 11 17240 302969 90308227
Gaze palsy 28.49 15.01 11 17240 1630 90609566
Off label use 28.43 15.01 111 17140 1102141 89509055
Sensorimotor disorder 28.38 15.01 9 17242 746 90610450
Palpitations 28.38 15.01 73 17178 136655 90474541
Folliculitis 28.25 15.01 3 17248 204350 90406846
Product dose omission issue 28.13 15.01 120 17131 291567 90319629
Nausea 27.46 15.01 327 16924 1109989 89501207
Migraine 27.28 15.01 89 17162 190303 90420893
Acute kidney injury 26.45 15.01 14 17237 320373 90290823
Intervertebral disc protrusion 26.16 15.01 29 17222 27167 90584029
Gastric bypass 26.10 15.01 11 17240 2043 90609153
Irritability 25.99 15.01 33 17218 35629 90575567
Periodic limb movement disorder 25.98 15.01 8 17243 602 90610594
Nervousness 25.59 15.01 32 17219 34024 90577172
Oropharyngeal blistering 25.53 15.01 9 17242 1034 90610162
Pyrexia 25.40 15.01 55 17196 660430 89950766
Neutropenia 25.06 15.01 6 17245 224898 90386298
Retching 24.88 15.01 24 17227 19135 90592061
Impaired healing 24.66 15.01 7 17244 234192 90377004
Abnormal dreams 24.62 15.01 19 17232 11238 90599958
Stevens-Johnson syndrome 24.34 15.01 29 17222 29347 90581849
Substance use 24.30 15.01 9 17242 1190 90610006
Wrong technique in product usage process 23.63 15.01 46 17205 71525 90539671
Type 2 diabetes mellitus 23.49 15.01 5 17246 203239 90407957
Victim of spousal abuse 23.45 15.01 4 17247 18 90611178
Death 23.02 15.01 32 17219 456519 90154677
Contraindicated product administered 22.29 15.01 17 17234 320122 90291074
Vision blurred 21.97 15.01 58 17193 110235 90500961
Nephrolithiasis 21.92 15.01 36 17215 49049 90562147
Nocturia 21.75 15.01 17 17234 10238 90600958
Therapeutic product effect decreased 21.65 15.01 13 17238 277558 90333638
Maternal exposure during pregnancy 21.60 15.01 22 17229 360041 90251155
Anger 21.33 15.01 19 17232 13701 90597495
Parasomnia 21.11 15.01 7 17244 669 90610527
Mania 20.85 15.01 19 17232 14105 90597091
Rotator cuff syndrome 20.78 15.01 20 17231 15899 90595297
Thrombocytopenia 20.61 15.01 7 17244 208718 90402478
Post-traumatic stress disorder 20.58 15.01 14 17237 6814 90604382
Gastrooesophageal reflux disease 20.54 15.01 74 17177 166263 90444933
Impaired gastric emptying 20.43 15.01 18 17233 12791 90598405
Wheezing 20.24 15.01 10 17241 238070 90373126
Appendicectomy 20.23 15.01 11 17240 3585 90607611
Therapeutic product effect increased 20.06 15.01 8 17243 1291 90609905
Major depression 19.92 15.01 16 17235 10019 90601177
Alcohol abuse 19.71 15.01 9 17242 2024 90609172
Perinatal depression 19.46 15.01 7 17244 852 90610344
Essential tremor 19.42 15.01 8 17243 1404 90609792
Toxicity to various agents 19.14 15.01 16 17235 287830 90323366
Arthropathy 19.13 15.01 25 17226 366217 90244979
Affective disorder 18.91 15.01 14 17237 7779 90603417
Concussion 18.52 15.01 16 17235 11075 90600121
Psychomotor hyperactivity 18.45 15.01 17 17234 12796 90598400
Drug diversion 18.11 15.01 7 17244 1040 90610156
Febrile neutropenia 18.08 15.01 4 17247 158345 90452851
Hyperhidrosis 17.99 15.01 62 17189 136243 90474953
Dyskinesia 17.97 15.01 28 17223 36506 90574690
Tachyphrenia 17.96 15.01 8 17243 1698 90609498
Central nervous system lesion 17.85 15.01 16 17235 11630 90599566
Urinary incontinence 17.38 15.01 28 17223 37538 90573658
Psoriatic arthropathy 17.38 15.01 11 17240 228324 90382872
Muscle spasms 17.29 15.01 94 17157 251789 90359407
Balance disorder 17.29 15.01 49 17202 97031 90514165
Generalised anxiety disorder 17.14 15.01 9 17242 2738 90608458
Extra dose administered 16.97 15.01 14 17237 9104 90602092
Nasal septum deviation 16.96 15.01 8 17243 1935 90609261
Neuralgia 16.70 15.01 25 17226 31475 90579721
Lung disorder 16.69 15.01 4 17247 149879 90461317
Hepatic enzyme increased 16.51 15.01 27 17224 360709 90250487
Disturbance in attention 16.43 15.01 31 17220 47078 90564118
Sleep attacks 16.31 15.01 4 17247 128 90611068
Rapid eye movement sleep behaviour disorder 16.19 15.01 5 17246 380 90610816
Abdominal pain 15.99 15.01 32 17219 395689 90215507
Knee operation 15.81 15.01 12 17239 6924 90604272
Hypersomnia 15.81 15.01 20 17231 21511 90589685
Product use issue 15.76 15.01 24 17227 329895 90281301
Infection 15.75 15.01 28 17223 362066 90249130
Musculoskeletal stiffness 15.73 15.01 20 17231 296512 90314684
Abnormal sleep-related event 15.70 15.01 6 17245 865 90610331
Tonsillolith 15.61 15.01 3 17248 29 90611167
Psychotic disorder 15.45 15.01 24 17227 31206 90579990
Dry eye 15.33 15.01 34 17217 57897 90553299
Therapeutic product effect incomplete 15.23 15.01 9 17242 193887 90417309
Dizziness 15.12 15.01 175 17076 589109 90022087
Hypertension 15.10 15.01 143 17108 457389 90153807
Ankle fracture 15.08 15.01 19 17232 20351 90590845
Product packaging issue 15.08 15.01 7 17244 1634 90609562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product administration interrupted 185.36 23.74 54 5547 4912 42610822
Sleep apnoea syndrome 144.83 23.74 66 5535 21542 42594192
Pre-existing condition improved 105.17 23.74 31 5570 2932 42612802
Depression 96.03 23.74 94 5507 111269 42504465
Anxiety 91.08 23.74 94 5507 118466 42497268
Narcolepsy 88.85 23.74 20 5581 643 42615091
Suicidal ideation 88.39 23.74 63 5538 48098 42567636
Somnambulism 60.25 23.74 21 5580 3394 42612340
Insomnia 52.68 23.74 71 5530 118182 42497552
Feeling jittery 47.56 23.74 19 5582 4479 42611255
Feeling abnormal 45.83 23.74 51 5550 69735 42545999
Somnolence 44.47 23.74 72 5529 141033 42474701
Therapeutic response unexpected 44.15 23.74 24 5577 11357 42604377
Surgery 41.69 23.74 27 5574 17589 42598145
Blood pressure increased 34.83 23.74 54 5547 101874 42513860
Bruxism 33.18 23.74 12 5589 2157 42613577
Snoring 32.58 23.74 14 5587 3959 42611775
Intentional product use issue 31.74 23.74 43 5558 71790 42543944
Migraine 30.74 23.74 26 5575 25388 42590346
Amnesia 30.18 23.74 27 5574 28410 42587324
Tremor 29.87 23.74 49 5552 96880 42518854
Palpitations 29.74 23.74 35 5566 50762 42564972
Headache 28.25 23.74 82 5519 239287 42376447
Rash 28.14 23.74 90 5511 276864 42338870
Cataplexy 26.84 23.74 7 5594 420 42615314
Hunger 26.72 23.74 10 5591 1978 42613756
Post-traumatic stress disorder 25.37 23.74 10 5591 2275 42613459
Hypertension 24.43 23.74 62 5539 167142 42448592

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product administration interrupted 315.03 16.37 96 13129 11196 110564878
Pre-existing condition improved 150.58 16.37 48 13177 6478 110569596
Anxiety 128.61 16.37 181 13044 344897 110231177
Sleep apnoea syndrome 127.44 16.37 72 13153 40375 110535699
Depression 122.03 16.37 169 13056 317166 110258908
Multiple sclerosis relapse 108.04 16.37 70 13155 50170 110525904
Feeling abnormal 105.98 16.37 119 13106 180592 110395482
Suicidal ideation 100.49 16.37 86 13139 93851 110482223
Somnambulism 99.58 16.37 35 13190 6370 110569704
Narcolepsy 97.22 16.37 25 13200 1563 110574511
Surgery 87.48 16.37 57 13168 41226 110534848
Somnolence 73.09 16.37 129 13096 297320 110278754
Cataplexy 64.76 16.37 17 13208 1152 110574922
Snoring 61.53 16.37 25 13200 6759 110569315
Enuresis 58.43 16.37 21 13204 4075 110571999
Fall 54.38 16.37 177 13048 603305 109972769
Tremor 53.94 16.37 91 13134 202141 110373933
Headache 53.75 16.37 228 12997 882149 109693925
Therapeutic response unexpected 53.16 16.37 34 13191 23809 110552265
Feeling jittery 51.25 16.37 28 13197 14694 110561380
Blood pressure increased 48.53 16.37 100 13125 258273 110317801
Memory impairment 43.98 16.37 82 13143 196862 110379212
Multiple sclerosis 41.46 16.37 30 13195 25668 110550406
Weight decreased 40.07 16.37 135 13090 467922 110108152
Head injury 39.22 16.37 36 13189 42981 110533093
Panic attack 38.28 16.37 30 13195 28910 110547164
Sleep paralysis 35.23 16.37 10 13215 908 110575166
Infusion related reaction 34.49 16.37 3 13222 381159 110194915
Product dose omission issue 34.13 16.37 100 13125 321682 110254392
Paranoia 33.56 16.37 25 13200 22349 110553725
Vitamin D deficiency 33.02 16.37 23 13202 18529 110557545
Seizure 31.82 16.37 77 13148 221108 110354966
Restless legs syndrome 31.43 16.37 25 13200 24601 110551473
Unevaluable event 31.29 16.37 37 13188 59190 110516884
Bruxism 30.77 16.37 14 13211 4980 110571094
Nausea 29.09 16.37 249 12976 1235441 109340633
Hangover 28.95 16.37 11 13214 2491 110573583
Illness 28.87 16.37 42 13183 82129 110493945
Sensorimotor disorder 28.60 16.37 9 13216 1163 110574911
Nervousness 28.20 16.37 28 13197 36823 110539251
Acute kidney injury 28.10 16.37 21 13204 635409 109940665
Neutropenia 26.79 16.37 6 13219 374614 110201460
Feeling drunk 26.45 16.37 13 13212 5487 110570587
Sleep-related eating disorder 26.36 16.37 8 13217 917 110575157
Insomnia 25.69 16.37 98 13127 360492 110215582
Gaze palsy 25.67 16.37 11 13214 3396 110572678
Abnormal dreams 25.49 16.37 17 13208 12763 110563311
Victim of spousal abuse 25.31 16.37 4 13221 18 110576056
Febrile neutropenia 24.93 16.37 4 13221 316763 110259311
Amnesia 24.91 16.37 45 13180 105363 110470711
Intentional dose omission 24.81 16.37 20 13205 20060 110556014
Impaired driving ability 24.65 16.37 13 13212 6357 110569717
Balance disorder 24.11 16.37 47 13178 116513 110459561
Intervertebral disc protrusion 22.98 16.37 22 13203 27676 110548398
Retching 22.68 16.37 20 13205 22662 110553412
Stress 22.42 16.37 43 13182 105305 110470769
Migraine 21.79 16.37 57 13168 171595 110404479
Dry eye 21.79 16.37 30 13195 55763 110520311
Palpitations 21.38 16.37 54 13171 159158 110416916
Initial insomnia 21.16 16.37 14 13211 10375 110565699
Treatment failure 20.73 16.37 4 13221 277230 110298844
Bipolar disorder 20.46 16.37 13 13212 8994 110567080
Off label use 20.04 16.37 102 13123 1500083 109075991
Concussion 19.83 16.37 14 13211 11524 110564550
Toxicity to various agents 19.82 16.37 17 13208 480538 110095536
Vision blurred 19.71 16.37 46 13179 128976 110447098
Lower respiratory tract infection 19.28 16.37 3 13222 243103 110332971
Rotator cuff syndrome 19.22 16.37 16 13209 16778 110559296
Hysterectomy 19.16 16.37 12 13213 8102 110567972
Drug intolerance 18.52 16.37 13 13212 406499 110169575
Muscle spasms 18.50 16.37 74 13151 278083 110297991
Product use in unapproved indication 18.24 16.37 16 13209 447361 110128713
Cervical radiculopathy 18.08 16.37 7 13218 1667 110574407
Hypersomnia 17.31 16.37 19 13206 28042 110548032
Urinary incontinence 17.31 16.37 25 13200 48562 110527512
Trigeminal neuralgia 17.18 16.37 9 13216 4343 110571731
Nocturia 17.03 16.37 15 13210 16975 110559099
Extra dose administered 16.94 16.37 13 13212 12146 110563928
Abdominal pain 16.84 16.37 22 13203 512967 110063107
Stevens-Johnson syndrome 16.51 16.37 24 13201 46877 110529197

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA13 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D064690 Wakefulness-Promoting Agents
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
CHEBI has role CHEBI:35337 central nervous system stimulant
CHEBI has role CHEBI:77567 eugeroic

Related Drugs by ATC class:

N06BA Centrally acting sympathomimetics 14 drugs
amfetamineatomoxetinedexamfetaminedexmethylphenidatefencamfaminfenetyllinefenozolonelisdexamfetaminemethamphetaminemethylphenidatemodafinilpemoline show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Sleepiness Due To Obstructive Sleep Apnea indication
Sleepiness Due To Shift Work Sleep Disorder indication
Suicidal thoughts contraindication 6471006
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Left ventricular hypertrophy contraindication 55827005
Hepatic failure contraindication 59927004
Psychotic disorder contraindication 69322001
Mania contraindication 231494001
Mitral valve prolapse contraindication 409712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.23 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR IC50 5.50 WOMBAT-PK CHEMBL
D(3) dopamine receptor GPCR Ki 4.41 CHEMBL
D(2) dopamine receptor GPCR EC50 6.92 WOMBAT-PK
Cytochrome P450 1A2 Enzyme WOMBAT-PK
Cytochrome P450 2C19 Enzyme WOMBAT-PK
Alpha-1B adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.49 CHEMBL

External reference:

IDSource
D03215 KEGG_DRUG
4026237 VANDF
CHEBI:77590 CHEBI
CHEMBL1201192 ChEMBL_ID
8474 INN_ID
DB06413 DRUGBANK_ID
V63XWA605I UNII
641465 RXNORM
116668 MMSL
23941 MMSL
241076 MMSL
d06842 MMSL
012231 NDDF
428694009 SNOMEDCT_US
429452005 SNOMEDCT_US
C0066677 UMLSCUI
D000077408 MESH_DESCRIPTOR_UI
9690109 PUBCHEM_CID
V63XWA605I INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3090 TABLET 50 mg ORAL NDA authorized generic 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3092 TABLET 150 mg ORAL NDA authorized generic 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3093 TABLET 200 mg ORAL NDA authorized generic 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3094 TABLET 250 mg ORAL NDA authorized generic 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3431 TABLET 50 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3432 TABLET 150 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3433 TABLET 250 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8029 TABLET 50 mg ORAL NDA authorized generic 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8037 TABLET 150 mg ORAL NDA authorized generic 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8045 TABLET 200 mg ORAL NDA authorized generic 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8053 TABLET 250 mg ORAL NDA authorized generic 28 sections
NUVIGIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-345 TABLET 150 mg ORAL NDA 24 sections
NUVIGIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-394 TABLET 250 mg ORAL NDA 24 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 42254-014 TABLET 50 mg ORAL NDA 24 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 55700-510 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 31 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60429-001 TABLET 50 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60429-002 TABLET 150 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60429-003 TABLET 200 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60429-004 TABLET 250 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60505-4846 TABLET 50 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60505-4847 TABLET 150 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60505-4849 TABLET 200 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 60505-4850 TABLET 250 mg ORAL NDA 29 sections
ARMODAFINIL HUMAN PRESCRIPTION DRUG LABEL 1 61919-562 TABLET 150 mg ORAL NDA authorized generic 17 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 61919-770 TABLET 150 mg ORAL ANDA 17 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-205 TABLET 50 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-215 TABLET 150 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-220 TABLET 200 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-225 TABLET 250 mg ORAL NDA 29 sections
Armodafinil Human Prescription Drug Label 1 65862-805 TABLET 50 mg ORAL ANDA 30 sections